Seaport Therapeutics, Inc. (SPTX)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Seaport Therapeutics: A Development-Arbitrage Platform With Two Layers Of Validation
Seaport Therapeutics leverages its Glyph platform to transform clinically validated molecules with poor delivery into proprietary, patent-protected prodrugs, reducing biological risk. GlyphAllo's Phase 2b BUOY-1 trial in MDD targets a differentiated profile, with top-line data expected in H1 2027 and a focus on anxious distress subpopulations. GlyphAgo's strong Phase 1 PK data and platform repeatability support SPTX's strategy, with Phase 2a in GAD set for H2 2026 and registration-enabling studies to follow.
Seaport Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Regan O'Neill Burkehill Global Management LP | 25,000 | $449,250 | $402,000 | -$47,250 | -10.52% |
| KJ Ken Joseph Braidwel LLP | 500,000 | $8.98M | $8.78M | -$205,000 | -2.28% |
 Christopher C. Powers Farther Finance Advisors, LLC | 334 | $7,885.74 | $5,410.8 | -$2,474.94 | -31.39% |
 Raymond Debbane Siren, L.L.C. | 1.1M | $19.68M | $19.28M | -$405,266.92 | -2.06% |
 James B. Tananbaum Foresite Capital Management VI LLC | 1.78M | $31.98M | $30.63M | -$1.35M | -4.23% |
Seaport Therapeutics, Inc. (SPTX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Seaport Therapeutics, Inc. ever had a stock split?
Seaport Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Daphne Zohar CEO | NASDAQ (NGS) Exchange | 81221K108 CUSIP |
| US Country | 58 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Seaport Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that focuses on advancing the development of innovative neuropsychiatric medicines. Founded in 2024 and located in Boston, Massachusetts, the company is dedicated to developing therapeutic candidates specifically targeting conditions such as depression and anxiety disorders. By utilizing its proprietary Glyph technology platform, Seaport Therapeutics aims to provide cutting-edge solutions in the realm of mental health.
The Glyph platform has been uniquely designed to enhance oral bioavailability, effectively bypass first-pass metabolism, and mitigate liver enzyme elevations or hepatotoxicity, addressing crucial side effects commonly associated with neuropsychiatric treatments. With all therapeutic candidates under development stemming from this advanced technology, the company's focus remains singularly on neuropsychiatric medicines, catering to clinicians and key opinion leaders in the healthcare sector.
Products and Services
- Therapeutic Candidate Development
Seaport Therapeutics is actively developing a range of therapeutic candidates aimed at treating depression and anxiety disorders. Each candidate is formulated utilizing the Glyph platform to ensure maximum efficacy and reduced side effects, providing hope for patients suffering from these common conditions.
- Glyph Technology Platform
The Glyph platform is at the core of Seaport Therapeutics’ innovation, which focuses on achieving oral bioavailability while circumventing first-pass metabolism. This technology not only enhances drug absorption but also minimizes the risk of hepatotoxicity and other adverse effects, making it a significant advancement in neuropsychiatric medication.
- Collaboration with Healthcare Professionals
Seaport Therapeutics engages with clinicians and key opinion leaders throughout the healthcare field to share insights and gather expertise. This collaboration is crucial for aligning their therapeutic developments with the real-world needs of healthcare providers and patients.
Contact Information
